Progressive multifocal leukoencephalopathy responsive to withdrawal of imatinib in a patient with FIP1L1-PDGFRA positive myeloid neoplasm
Published inLeukemia and Lymphoma, vol. 61, no. 9, p. 2226-2229
Publication date2020
Keywords
- Humans Hypereosinophilic Syndrome* Imatinib Mesylate / therapeutic use Leukoencephalopathy
- Progressive Multifocal* / diagnosis Leukoencephalopathy
- Progressive Multifocal* / drug therapy Myeloproliferative Disorders* / complications Myeloproliferative Disorders* / diagnosis Myeloproliferative Disorders* / drug therapy Neoplasms* Oncogene Proteins
- Fusion / genetics Oncogene Proteins
- Fusion / metabolism Receptor
- Platelet-Derived Growth Factor alpha / genetics Receptor
- Platelet-Derived Growth Factor alpha / metabolism mRNA Cleavage and Polyadenylation Factors / genetics
Affiliation entities
Citation (ISO format)
BLUM, Sabine et al. Progressive multifocal leukoencephalopathy responsive to withdrawal of imatinib in a patient with FIP1L1-PDGFRA positive myeloid neoplasm. In: Leukemia and Lymphoma, 2020, vol. 61, n° 9, p. 2226–2229. doi: 10.1080/10428194.2020.1759052
Main files (1)
Article (Published version)
Identifiers
- PID : unige:154825
- DOI : 10.1080/10428194.2020.1759052
- PMID : 32364409
Journal ISSN1026-8022
